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Editorial on the Research Topic
The Role of ncRNAs in Solid Tumors Prognosis: From Laboratory to Clinical Utility
EDITORIAL
Today we know that non-coding RNAs (ncRNAs) represent most of the transcribed human genome
and participate in relevant cellular processes. NcRNAs regulate from RNA transcription to protein
translation, have important epigenetic roles or facilitate protein–protein interactions among other
functions. In consequence, their dysregulation has been associated with tumor development and
progression. Recently, their expression has also been detected in body fluids, opening the use of
circulating ncRNAs for diagnosis and for evaluation and monitoring cancer prognosis.
The present Research Topic titled “The Role of ncRNAs in Solid Tumors’ Prognosis: From
Laboratory to Clinical Utility” features 48 scientific studies (originals, meta-analysis and reviews)
that display different functions that ncRNAs can make in the carcinogenesis process and how they
can affect cancer treatment response and therefore, be of utility as cancer biomarkers in solid
tumors. This topic includes two groups of papers: 1) articles describing mechanisms by which
ncRNAs regulate cancer development and progression; and 2) articles that use both publicly
available data (TCGA or GEO) or own researchers’ collected datasets to identify and validate
ncRNA prognostic signatures for several cancers.
NcRNAs can be classified in two major groups according to their size; small ncRNAs and long
ncRNAs (lncRNAs); the last include a very heterogeneous group that have in common that they are
longer than 200 nucleotides. From the small ncRNA group, the best studied class is microRNAsFebruary 2021 | Volume 10 | Article 6313161
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as long precursors finally processed to an 18–22 nucleotide
product. Although a lot of different functions have been
described for miRNAs, the most relevant one is the participation
in the translation process, where they inhibit in a sequence-
dependent manner the mRNA translation to protein of their
target mRNAs. Furthermore, their utility as cancer biomarkers in
solid tumors has been extensively studied in both tumor and liquid
biopsy. Several authors have addressed this issue in this Research
Topic. In the next paragraphs we are summarizing the main
achieved results.
Prof. Zhao and colleagues reviewed the contribution of miR-
27a to solid tumor diagnosis and prognosis and discussed the
possibilities to use this miRNA for therapy and drug design
(Zhang J. et al.). Another review article by Xiang et al.
commented on the double function (tumor suppressor or
oncogene) of miR-186. They explained that while in most of the
tumors miR-186 is a tumor suppressor miRNA, in endometrial
and cutaneous squamous cell carcinomas it acts as an oncogene. It
was discussed in the review article that a dose dependent-effect on
both miRNA and its target abundance may explicate the opposing
role of miR-186 depending on the tumor type. In an original study,
Liu C. et al. used a different bioinformatic approach integrating
miRNA targets and phenotypes to identify part of the miR-622
targetome. In silico data was used to study in breast cancer in vitro
models (viability, migration, etc.) the role of miR-622. In another
study, Di et al., using TCGA and GEO, identified a 9-miRNA
signature including miR-29c, -92a, -101, -148a, -200a, -210, -338,
-424 and -492, with diagnostic and prognostic utility for patients
with colorectal cancer (CRC). They validated the signature and
specifically studied the involvement in the metastatic process of
miR-200a-3p using different in vitro experiments.
In relation to miRNAs involved in treatment response, Cheng
and Shen identified miR-335 (downregulated) as a factor involved
in radiotherapy resistance in melanoma through regulation of
ROCK1. Lin et al. observed that miR-199b-5p was involved in
angiogenesis regulation (antiangiogenic factor) in breast cancer by
targeting ALK1 and suggested that this miRNA could be used as
antiangiogenic treatment response biomarker. Gao et al.’s results
indicated that by regulation of TRIM27 and related PI3K/Akt
pathway, this miRNA modulates in vitro aggressiveness of
hepatocellular carcinoma (HCC). Prof. Fan, using in vivo and in
vitro experiments, found thatmiR-24-3pwas involved inpancreatic
ductal adenocarcinoma (PDAC) progression through LAMB3
downregulation (Huang et al.). Similarly, but in breast cancer,
Prof. Wei revealed that miR-15b-5p regulating heparanase-2
(HPSE2) could be also a progression biomarker (Wu B. et al.).
Prof. Lu led a research that associated serum miR-222-3p with
pathological complete response, survival, and cardiotoxicity in
HER2-positive breast cancer patients receiving trastuzumab-
based neoadjuvant treatment (Zhang S. et al.). Prof. Edwards and
his team, combining profiling and functional studies, identified key
miRNAs for prostate cancermetastasis (Rao et al.). All these studies
reinforced the significance and clinical utility ofmiRNAs in cancer.
The other articles sent to our Research Topic, specifically 29
articles, focused on the study of lncRNAs. LncRNAs are aFrontiers in Oncology | www.frontiersin.org 2heterogeneous class of ncRNAs since they included all ncRNAs
longer than 200 nt (Gong and Jang). We have summarized the
principal results by tumor type in the following lines.
Several authors have studied lncRNAs in non-small cell lung
cancer (NSCLC), and different lncRNAs have been identified.
TGFb-induced lncRNA TBULC enhancedmigration and invasion
in vitro, and its higher levels were associated with shorter overall
survival (OS) in patient samples (Zheng S. et al.). LincRNA00494
repressed proliferation by regulation of the miR-150-3p/SRCIN1
axis (Dong J. et al.).
In CRC, a combination of AP003555.2, AP006284.1, and
LINC01602 was identified and validated for predicting OS
(Liu Y. et al.). MIR4435-2HG was also related to OS and in
vitro studies showed that the oncogenic role of this lncRNA was
performed trough miR-206 sponging and, therefore by
modulation of YAP1 protein levels (Dong et al.). Another
lincRNA with oncogenic potential in CRC was linc00662 which
performed a ceRNA function on miR-497-5p/AVL9 axis (Wang
H. et al.). In a similar way, MIR570MG, by controlling miR-145
levels and consequently modulating the SMAD3 pathway, plays a
role in regorafenib treatment resistance (Wei et al.). In contrast to
the previous ones,MEG3 lncRNA was acting as tumor suppressor
in CRC where its low levels were associated with shorter OS.
MEG3 lncRNA expression was affected by vitamin D and their
function was related to glycolysis in CRC (Zuo et al.).
In breast cancer, LINC00993 was identified by in vitro and in
vivo studies as a tumor suppressor gene in which low levels were
related to shorter OS in tri-negative breast cancer patients (Guo
et al.). In contrast, MRPS30-DT lncRNA acted as oncogene by
regulating Jab1/Cops5, and its high levels were associated with
worse outcome (Wu B. et al.). Another oncogenic lncRNA was
Linc00668 which promoted a more malignant phenotype in breast
cancer cells through regulation of SND1. Moreover, their higher
levels were related with treatment resistance in cell lines and with
shorter disease-free survival in patient samples (Qian et al.). Lastly,
DCST1-AS1 enhanced epithelial–mesenchymal transition by
ANXA1 regulation and promoted in vitro treatment resistance in
metastatic breast cancer cells (Tang et al.). Also in breast cancer, but
in the context of the study of the antitumorigenic role of Huaier, a
traditional Chinese medicine (see NCI drug dictionary for more
detailed information, https://www.cancer.gov/publications/
dictionaries/cancer-drug/def/huaier-extract-granule), Wang W.
et al. identified a Huaier-related lncRNA, linc00339, which acting
through the miR-4656/CSNK2B axis, participates in the
antiproliferative effect of this drug in breast cancer cells.
In a more diverse set of tumor types, several authors identified
interesting lncRNAs with potential use as diagnostic or
prognostic markers. PICSAR, LINC00319, THOR, AK144841,
MALAT1, LINC10148, and HOTAIR were found upregulated,
while TINCR, LINC00520, and GAS5 were downregulated in
cutaneous squamous cell carcinoma and correlated with several
histological subtypes (Wang Y. et al.). In esophageal squamous cell
carcinoma a 6-lncRNA signature associated with metabolic
syndrome including AC005091.1, SNHG6, AC091544.4,
DNAJB5-DT, HTT-AS, and ANKRD10-IT1, impacted prognosis
in these patients (Liu Y. et al.). Another prognostic signature wasFebruary 2021 | Volume 10 | Article 631316
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studies with one of the lncRNAs of the signature, GACAT3, to
partially validate the functional relevance of the identified signature.
In PDAC, Zhou C. et al. identified and validated in two cohorts a
signature of five lncRNAs: RP11-159F24.5, RP11-744N12.2, RP11-
388M20.1, RP11-356C4.5, and CTC-459F4.9 as independent
prognostic markers for OS. In nephroblastoma, Wang J. et al.
identified lncRNAs with prognostic significance by the use of
multiomic integration data, and in a similar way, but in gastric
cancer Pan H. et al. identified networks of lncRNAs/miRNAs/
mRNAs involved in the tumorigenesis process and focused in the
in vitro validation of the ADAMTS9-AS2/miR-372/CADM2 axis.
Interestingly, most of the previously commented lcnRNA
studies are related to the ceRNA function of lncRNAs, and
they took advantage of public available databases, such as
TCGA or GEO, to connect the experimental findings with the
clinical utility of the potential lncRNA biomarkers identified.
Several authors have implemented review or meta-analysis
studies to emphasize the relevant role of lncRNA in cancer. Lu
et al. focused on the revision of lncRNA involved in metabolic
cancer-related processes. Zhou Y. et al. described the most relevant
lncRNAs associated with cancer-immunology, specifically PD-1/
PD-L1 and CTLA-4 pathways, and their relevance for
immunotherapy resistance. In the same context, Luo et al.
emphasized the role of lncRNAs in the modulation of the
immunosuppressive microenvironment and discussed the
potential clinical applications of these lncRNAs in cancer
treatment by immunotherapy. Peng et al. emphasized the most
relevant lncRNAs related to thyroid cancer and their potential
interactions with mRNAs and miRNAs. Finally, three papers
performed a meta-analysis and a review to highlight the
relevance of three lncRNAs in cancer patients’ survival; one
focused on SOX2-OT lncRNA (Li Y. et al.), another on
PANDAR lncRNA (Han et al.), and the last one focused on
DANCR lncRNA (Jin et al.). The three studies highlighted that the
overexpression of the three individual lncRNAs was related to
advanced disease and worst patient outcome in several cancers.
Four articles focused on small nucleolar RNA (snRNA) host
genes (SNHGs), a class of lncRNAs derived from the non-
processing of the RNA sequences of the genes coding for
snRNAs. On one hand, one article from Zimta et al. reviewed
the oncogenic potential of this gene family in various cancers and
highlighted their potential as viable biomarkers. On the other hand,
three articles focused on the study of the oncogenic role of specific
SNHGs: 1) SNHG17 was linked to carcinogenesis in prostate
cancer through sponging miR-144, which regulates CD51 (Bai
et al.); 2) SNHG12 modulated MDM4 and p53 pathways by acting
on miR-129-5p in renal cell carcinoma (Wu Z. et al.); and 3)
SNHG18 in gliomas was linked to ENO1 (Zheng R. et al.). In
summary, we can state that the four studies confirmed the
relevance of SNHGs, which knockdown might be considered as a
new cancer therapeutic option that deserves further investigation.
A more atypical group of lncRNAs are circular RNAs
(circRNAs), which are characterized by the formation of a
functional circular structure, generally as a result of a backsplicing
process, without the 5′ cap or 3′ poly A tail (Liu J. et al.). TheirFrontiers in Oncology | www.frontiersin.org 3implication in the tumorigenesis process has been recently
confirmed, and their potential as cancer biomarkers has been
understudied to date. Some articles included in this Research
Topic have been dedicated to the study of circRNAs in different
tumors. Wan et al. emphasized the role of circRNAs in
osteosarcoma. Wang X. et al. identified and validated in HCC,
hsa_circ_0000517 as a prognostic marker by bioinformatics, qRT-
PCR, and Sanger sequencing. In CRC, comparing the exosomal
cargo pre- and post-surgery, Pan B. et al. observed that hsa-circ-
0004771 levels become downregulated after surgery, indicating a
potential role for this exosomal circRNA on diagnosis and on
disease follow-up. In another study, Yu et al. performed a profile
of circRNAs in pheochromocytomas and paragangliomas and
observed that the ceRNA function performed by the identified
circRNAswas relatedwith thepathogenesisprocess by regulationof
the epigenetics processes mediated by histonemethylation. Finally,
in neuroblastoma, the in vitro and in vivo study of Yang et al.
identified the circDGKB as an oncogene involved in disease
progression by regulation of miR-873 and its target GLI1.
Despite the sharp increase in lncRNA-related publications
(Dai et al.), including the ones from the present Research Topic,
deeper functional and structural studies are still needed to
understand the principles of the emerging role of lncRNAs,
which is a heterogeneous group with a great potential in
cancer prognosis and therapeutics. Therefore, we still need to
investigate more and more novel ncRNAs as biomarkers or
targets for cancer treatment and control. Let’s go ahead with
translational researches of ncRNAs for cancer!AUTHOR CONTRIBUTIONS
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